Denosumab for joints and bones |
| |
Authors: | E Michael Lewiecki |
| |
Institution: | (1) New Mexico Clinical Research & Osteoporosis Center, 300 Oak Street NE, Albuquerque, NM 87106, USA |
| |
Abstract: | Denosumab is an investigational, fully human monoclonal antibody with a high affinity and specificity for receptor activator
of nuclear factor κ B ligand (RANKL), a cytokine member of the tumor necrosis factor family. RANKL, an essential mediator
of osteoclast formation, function, and survival, plays a major role in the pathogenesis of postmenopausal osteoporosis, structural
damage in rheumatoid arthritis, and bone loss associated with other skeletal disorders. Denosumab suppresses bone turnover
by inhibiting the action of RANKL on osteoclasts. Denosumab reduces bone turnover and increases bone mineral density in postmenopausal
women with low bone mineral density, reduces fracture risk in women with postmenopausal osteoporosis, and inhibits structural
damage in patients with rheumatoid arthritis when added to ongoing methotrexate treatment. It is generally well tolerated,
with a good safety profile. Adverse and serious adverse events, including infections and malignancy, are similar in patients
treated with denosumab or placebo. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|